Search

Carla V Rothlin

from New Haven, CT
Age ~51
Get Report
Also known as:
Carla Rothlyn, Othlyn R Carla
Phone and address:
100 Temple St APT 4, New Haven, CT 06510
Related to:
Delos Angeles RothlinRodolfo P Rothlin
Connected to:
Laura A Rothlin, 73Aaron C Rothlisberger, 40Faith Rothlisberger, 68Abby M Rothman, 42Addie R Rothmann, 44Alyssa M Rothman, 30Andy Rothman, 74Ashley Rothmann, 31Bryan A Rothman, 47Chuck E Rothman, 64

Carla Rothlin Phones & Addresses

  • 100 Temple St APT 4, New Haven, CT 06510
  • Del Mar, CA

Work

Company: Yale university Aug 2019 Position: Professor of immunobiology

Education

School / High School: University of Buenos Aires

Skills

Molecular Biology • Cell Biology • Cell Culture • Life Sciences • Biochemistry • Western Blotting • Molecular Cloning • Pcr • Immunohistochemistry • Confocal Microscopy

Industries

Research

Resumes

Resumes

Carla Rothlin Photo 1

Professor Of Immunobiology

View page
Location:
221 Whitney Ave, New Haven, CT 06511
Industry:
Research
Work:
Yale University
Professor of Immunobiology
Salk Institute For Biological Studies 2002 - 2009
Postdoc
Education:
University of Buenos Aires
Skills:
Molecular Biology
Cell Biology
Cell Culture
Life Sciences
Biochemistry
Western Blotting
Molecular Cloning
Pcr
Immunohistochemistry
Confocal Microscopy

Publications

Us Patents

Use Of Tam Receptor Inhibitors As Antimicrobials

View page
US Patent:
20100247554, Sep 30, 2010
Filed:
Nov 7, 2008
Appl. No.:
12/741812
Inventors:
Greg E. Lemke - La Jolla CA, US
John A.T. Young - San Diego CA, US
Carla V. Rothlin - Del Mar CA, US
Suchita Bhattacharyya - San Diego CA, US
International Classification:
A61K 39/395
A61K 31/4196
A61K 31/519
G01N 33/531
A61P 31/12
A61P 31/04
A61P 33/00
A61P 37/04
US Classification:
4241721, 514383, 5142621, 5142651, 435 721
Abstract:
This disclosure concerns antimicrobial compositions and methods for immunoenhancement, for example methods of increasing production of a type I interferon (IFN) in response to pathogen infection, by administration of a TAM receptor inhibitor. In certain embodiments, the disclosure concerns methods of using a TAM receptor inhibitor to treat a viral or bacterial infection in a subject.

Use Of Tam Receptor Inhibitors As Immunoenhancers And Tam Activators As Immunosuppressors

View page
US Patent:
20100266604, Oct 21, 2010
Filed:
Nov 7, 2008
Appl. No.:
12/741797
Inventors:
Carla V. Rothlin - Del Mar CA, US
Greg E. Lemke - La Jolla CA, US
Assignee:
The Salk Institute for Biological Studies - La Jolla CA
International Classification:
A61K 39/395
A61K 39/00
G01N 33/574
A61P 35/00
A61P 31/00
A61P 37/00
US Classification:
4241431, 4241841, 435 723
Abstract:
This disclosure concerns compositions and methods for immunoenhancement and/or immunosuppression. In certain embodiments, the disclosure concerns methods of using a TAM receptor inhibitor for immunoenhancement, for example as a vaccine adjuvant, for the treatment of sepsis, or for treating an immunocompromised subject. Also disclosed are methods of screening for immunoenhancing agents. In other embodiments, the disclosure concerns methods of using a TAM receptor agonist for immunosuppression, for example as a treatment for an autoimmune disorder, for the treatment of an allergy, or for treating graft-versus-host disease in a subject. Also disclosed are methods of screening for immunosuppressive agents.

Use Of Tam Receptor Inhibitors As Antimicrobials

View page
US Patent:
20130251734, Sep 26, 2013
Filed:
Mar 8, 2013
Appl. No.:
13/790191
Inventors:
John A.T. Young - San Diego CA, US
Carla V. Rothlin - New Haven CT, US
Suchita Bhattacharyya - San Diego CA, US
Assignee:
The Salk Institute for Biological Studies - La Jolla CA
International Classification:
A61K 39/395
A61K 31/4196
A61K 31/519
US Classification:
4241721, 5142621, 514383, 5142651
Abstract:
This disclosure concerns antimicrobial compositions and methods for immunoenhancement, for example methods of increasing production of a type I interferon (IFN) in response to pathogen infection, by administration of a TAM receptor inhibitor. In certain embodiments, the disclosure concerns methods of using a TAM receptor inhibitor to treat a viral or bacterial infection in a subject.

Regulating The Interaction Between Tam Ligands And Lipid Membranes With Exposed Phosphatidyl Serine

View page
US Patent:
20170129947, May 11, 2017
Filed:
Sep 20, 2016
Appl. No.:
15/270813
Inventors:
- La Jolla CA, US
- New Haven CT, US
Benedikt Vollrath - San Diego CA, US
Carla V. Rothlin - New Haven CT, US
Assignee:
Salk Institute for Biological Studies - La Jolla CA
Kolltan Pharmaceuticals, Inc. - New Haven CT
International Classification:
C07K 16/18
A61K 45/06
A61K 39/395
Abstract:
The present disclosure provides methods for modulating the interaction between a TAM ligand and a lipid membrane containing phosphatidyl serine (PtdSer). In one example, such methods use a TAM receptor agonist having a PtdSer-containing lipid bilayer membrane with Gas6 and/or Protein S bound to the membrane to activate signaling from one or more TAM receptors and treat an autoimmune disease. In another example, methods are provided for treating a subject with a pathological condition characterized by overactivation of TAM signaling and/or reduction in Type I IFN response, such as infection by an enveloped virus, by use of agents that decrease the interaction between a TAM ligand and PtdSer. Also provided are methods for classifying a virus as susceptible to anti-TAM therapy. Methods of identifying an agent that blocks virus infectivity are also provided.

Regulating The Interaction Between Tam Ligands And Lipid Membranes With Exposed Phosphatidyl Serine

View page
US Patent:
20150164800, Jun 18, 2015
Filed:
Jul 23, 2013
Appl. No.:
14/416801
Inventors:
- La Jolla CA, US
- New Haven CT, US
Benedikt Vollrath - San Diego CA, US
Carla V. Rothlin - New Haven CT, US
Assignee:
Xetrios Therapeutics, Inc. - New Haven CT
Salk Institute For Biological Studies - La Jolla CA
International Classification:
A61K 9/127
C12Q 1/02
Abstract:
The present disclosure provides methods for modulating the interaction between a TAM ligand and a lipid membrane containing phosphatidyl serine (PtdSer). In one example, such methods use a TAM receptor agonist having a PtdSer-containing lipid bilayer membrane with Gas6 and/or Protein S bound to the membrane to activate signaling from one or more TAM receptors and treat an autoimmune disease. In another example, methods are provided for treating a subject with a pathological condition characterized by overactivation of TAM signaling and/or reduction in Type I IFN response, such as infection by an enveloped virus, by use of agents that decrease the interaction between a TAM ligand and PtdSer. Also provided are methods for classifying a virus as susceptible to anti-TAM therapy. Methods of identifying an agent that blocks virus infectivity are also provided.
Control profile
Carla V Rothlin from New Haven, CT, age ~51 Get Report